Skip to main content

Probing the pathogenesis of leukemia

Feb. 27, 2014, 8:00 AM


The oncogene LMO2 is deregulated in the majority of human acute T-cell leukemia (T-ALL) cases. To explore the pathophysiology of T-ALL – and search for other oncogenes involved in the disease – Utpal Davé, M.D., assistant professor of Medicine, and colleagues generated transgenic mice expressing high levels of Lmo2 (the mouse version of LMO2) in T-cells.

The investigators analyzed gene expression in the leukemias that developed in these mice and found two patterns of expression. One showed activation of Lyl1, Hhex and Mycn – genes that are also expressed in human Early T-cell Precursor ALL (ETP-ALL), a treatment-resistant subtype of the disease. The alternate pathway involved increased expression of Notch1 and its targets. The investigators discovered that Hhex is a target of Lmo2 and showed that inactivation of Hhex in the Lmo2 transgenic mice reduced T-ALL development – demonstrating that Hhex is a crucial mediator of Lmo2’s oncogenic function.

The study, reported Jan. 21 in PLOS ONE, reveals gene clusters important in T-ALL pathophysiology and provides a model for the highly treatment-resistant ETP-ALL subtype.

This research was supported by a VA Merit award from the Department of Veterans Affairs, and by grants from the National Institutes of Health (HL089403), the Leukemia & Lymphoma Society and the Vanderbilt-Ingram Cancer Center.

Send suggestions for articles to highlight in Aliquots and any other feedback about the column to

Recent Stories from VUMC News and Communications Publications

Vanderbilt Medicine
VUMC Voice